BioRestorative Therapies Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $0.01
50-Day Range
MA: $0.02
52-Week Range
Now: $0.01
Volume19.35 million shs
Average Volume62.17 million shs
Market Capitalization$20.66 million
P/E RatioN/A
Dividend YieldN/A
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Year FoundedN/A



Sales & Book Value

Annual Sales$110,000.00
Book Value($0.68) per share



Outstanding Shares1,639,626,000
Market Cap$20.66 million
Next Earnings DateN/A
OptionableNot Optionable


BioRestorative Therapies, Inc. (BRTXQ)
October 23, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1923rd out of 2,011 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

25th out of 26 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BRTXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for BRTXQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioRestorative Therapies (OTCMKTS:BRTXQ) Frequently Asked Questions

What stocks does MarketBeat like better than BioRestorative Therapies?

Wall Street analysts have given BioRestorative Therapies a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioRestorative Therapies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are BioRestorative Therapies' key executives?

BioRestorative Therapies' management team includes the following people:
  • Mr. Mark R. Weinreb M.S., Chairman, CEO & Pres (Age 67, Pay $407.2k)
  • Mr. Robert Paccasassi, VP of Quality & Compliance (Age 51, Pay $233.95k)
  • Mr. Francisco J. Silva, Chief Scientist and VP of R&D (Age 45, Pay $310.5k)
  • Dr. Wayne J. Olan, Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

Who are some of BioRestorative Therapies' key competitors?

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTXQ."

How do I buy shares of BioRestorative Therapies?

Shares of BRTXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioRestorative Therapies' stock price today?

One share of BRTXQ stock can currently be purchased for approximately $0.01.

How much money does BioRestorative Therapies make?

BioRestorative Therapies has a market capitalization of $20.66 million and generates $110,000.00 in revenue each year.

How many employees does BioRestorative Therapies have?

BioRestorative Therapies employs 8 workers across the globe.

What is BioRestorative Therapies' official website?

The official website for BioRestorative Therapies is www.biorestorative.com.

Where are BioRestorative Therapies' headquarters?

BioRestorative Therapies is headquartered at 40 MARCUS DRIVE, MELVILLE NY, 11747.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at 631-760-8100 or via email at [email protected]

This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.